These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7639058)

  • 41. Disease severity affects obstacle crossing in people with Parkinson's disease.
    Vitório R; Lirani-Silva E; Baptista AM; Barbieri FA; dos Santos PC; Teixeira-Arroyo C; Gobbi LT
    Gait Posture; 2014; 40(1):266-9. PubMed ID: 24671005
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cognitive impairment in early-stage non-demented Parkinson's disease patients.
    Pfeiffer HC; Løkkegaard A; Zoetmulder M; Friberg L; Werdelin L
    Acta Neurol Scand; 2014 May; 129(5):307-18. PubMed ID: 24117192
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Validating the Berg Balance Scale for patients with Parkinson's disease: a key to rehabilitation evaluation.
    Qutubuddin AA; Pegg PO; Cifu DX; Brown R; McNamee S; Carne W
    Arch Phys Med Rehabil; 2005 Apr; 86(4):789-92. PubMed ID: 15827933
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.
    Jin L; Wang J; Zhao L; Jin H; Fei G; Zhang Y; Zeng M; Zhong C
    Brain; 2011 Jan; 134(Pt 1):50-8. PubMed ID: 21109502
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dopamine transporter density is decreased in parkinsonian patients with a history of manganese exposure: what does it mean?
    Kim Y; Kim JM; Kim JW; Yoo CI; Lee CR; Lee JH; Kim HK; Yang SO; Chung HK; Lee DS; Jeon B
    Mov Disord; 2002 May; 17(3):568-75. PubMed ID: 12112209
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pathogenesis of Parkinson's disease.
    Riederer P; Lange KW
    Curr Opin Neurol Neurosurg; 1992 Jun; 5(3):295-300. PubMed ID: 1623255
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bladder symptoms assessed with overactive bladder questionnaire in Parkinson's disease.
    Iacovelli E; Gilio F; Meco G; Fattapposta F; Vanacore N; Brusa L; Giacomelli E; Gabriele M; Rubino A; Locuratolo N; Iani C; Pichiorri F; Colosimo C; Carbone A; Palleschi G; Inghilleri M
    Mov Disord; 2010 Jul; 25(9):1203-9. PubMed ID: 20310046
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease.
    Santos-García D; de la Fuente-Fernández R
    J Neurol Sci; 2013 Sep; 332(1-2):136-40. PubMed ID: 23890935
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Decreased serum proNGF concentration in patients with Parkinson's disease.
    Xu XM; Dong MX; Feng X; Liu Y; Pan JX; Jia SY; Cao D; Wei YD
    Neurol Sci; 2018 Jan; 39(1):91-96. PubMed ID: 29052090
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of sleep-related symptoms on clinical motor subtypes and disability in Parkinson's disease: a multicentre cross-sectional study.
    Suzuki K; Okuma Y; Uchiyama T; Miyamoto M; Sakakibara R; Shimo Y; Hattori N; Kuwabara S; Yamamoto T; Kaji Y; Hirano S; Kadowaki T; Hirata K;
    J Neurol Neurosurg Psychiatry; 2017 Nov; 88(11):953-959. PubMed ID: 28847794
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital.
    Ojo OO; Oladipo OO; Ojini FI; Sanya EO; Danesi MA; Okubadejo NU
    West Afr J Med; 2011; 30(5):319-24. PubMed ID: 22752818
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Environmental toxins accelerate Parkinson's disease onset.
    Rajput AH
    Neurology; 2001 Jan; 56(1):4-5. PubMed ID: 11148226
    [No Abstract]   [Full Text] [Related]  

  • 53. Quality of life and Parkinson's disease: Philippine translation and validation of the Parkinson's disease questionnaire.
    Suratos CTR; Saranza GRM; Sumalapao DEP; Jamora RDG
    J Clin Neurosci; 2018 Aug; 54():156-160. PubMed ID: 29907384
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [A case of welder presenting with parkinsonism after chronic manganese exposure].
    Sato K; Ueyama H; Arakawa R; Kumamoto T; Tsuda T
    Rinsho Shinkeigaku; 2000 Nov; 40(11):1110-5. PubMed ID: 11332192
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Environment, mitochondria, and Parkinson's disease.
    Sherer TB; Betarbet R; Greenamyre JT
    Neuroscientist; 2002 Jun; 8(3):192-7. PubMed ID: 12061498
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
    Luquin MR; Scipioni O; Vaamonde J; Gershanik O; Obeso JA
    Mov Disord; 1992; 7(2):117-24. PubMed ID: 1350058
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
    Morissette M; Morin N; Grégoire L; Rajput A; Rajput AH; Di Paolo T
    Biochem Pharmacol; 2016 Jun; 109():62-69. PubMed ID: 27038656
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reliability of patient completion of the historical section of the Unified Parkinson's Disease Rating Scale.
    Louis ED; Lynch T; Marder K; Fahn S
    Mov Disord; 1996 Mar; 11(2):185-92. PubMed ID: 8684390
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Searching for a relationship between manganese and welding and Parkinson's disease.
    Jankovic J
    Neurology; 2005 Jun; 64(12):2021-8. PubMed ID: 15985567
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.
    Giladi N; Nicholas AP; Asgharnejad M; Dohin E; Woltering F; Bauer L; Poewe W
    J Parkinsons Dis; 2016 Oct; 6(4):741-749. PubMed ID: 27567886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.